Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Ondansetron Orally Disintegrating Tablets are used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, or surgery. Consumers typically purchase this product to manage nausea effectively.
The hazard arises from the blister packs being inadequately sealed, which can cause tablets to fall out. This defect can lead to improper dosing or ingestion, posing a risk to patients.
This recall is not part of a broader industry pattern.
The recall affects consumers by necessitating the immediate cessation of use, which may disrupt their treatment plans. It raises safety concerns regarding the integrity of medication packaging.
The lot number and expiration date are typically found on the bottom or back of the product packaging.
Refund or replacement processing may take 4-6 weeks after returning the product.
Keep receipts, correspondence with the company, and photos of the product as evidence.
ONDANSETRON Orally Disintegrating Tablets, USP, 4mg are packaged in boxes containing 30 tablets (3 blistercards with 10 tablets each). The product is manufactured for Glenmark Pharmaceuticals Inc., USA, and sold nationwide in the United States.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals Inc. USA recalls theophylline extended-release 400 mg tablets after dissolution test failures. The recall covers 22,656 bottles distributed nationwide in the United States. Consumers should stop using the product and contact Glenmark for guidance.
Glenmark Pharmaceuticals Inc. recalls 6,432 bottles of Carvedilol Tablets, USP, 12.5 mg, distributed nationwide in the United States. The recall concerns CGMP deviations and the presence of a nitrosamine impurity above the acceptable intake level. Consumers should stop taking the product and contact Glenmark for guidance.
Glenmark Pharmaceuticals Inc., USA recalls 17,496 bottles of Carvedilol tablets sold nationwide after NNCI impurity exceeded FDA limits. The recall covers lot numbers 17241257, 17241258, and 17241279 with Exp. Date 06/2026. Consumers should stop using the product and contact Glenmark or their healthcare provider for guidance.